Forum on Drug Discovery, Development, and Translation 2014 Annual Report (2015) / Chapter Skim
Currently Skimming:
Looking Forward: Forum Activities in 2015
Looking Forward: Forum Activities in 2015
Pages 6-11
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 6... ...
The pharmaceutical industry offers many opportunities for disruption in each of these areas. The Forum has convened an action collabora tive that has set out to identify and highlight potentially breakthrough ideas and visionary approaches to the "drug development and translational science enter prise of the future." The effort has addressed new technologies (e.g., biosensors, apps and telemetry, synthetic biology, new delivery technologies)
|
From page 7... ...
It could also facilitate ongoing discussion to help frame, map, and synergize activities across the biomedical innovation ecosystem. Defining key terms and 2007 June 27–28 October 24–25 Forum Meeting #5 Forum Meeting #6
|
From page 8... ...
Sharing Clinical Trial Data -- Action Collaborative Sharing clinical trial data can facilitate more efficient and effective development of better medicines, diagnostics, and procedures for the ultimate benefit of patients. At the same time, sharing data presents risks, burdens, and challenges that need to be April 23–24 Workshop: Emerging Safety October 15–16 Science, FDA (Forum Meeting #7)
|
From page 9... ...
The workshop will explore current regulatory science priorities and strategies in federal, academic, and private sector settings; consider the current state of regulatory science as a discipline; explore the core components of a robust discipline of innovative regulatory science; consider gaps and key opportunities to address needs to support the discipline of innovative regulatory science; and examine needs and barriers to collaboration among, across, and within the public and private sectors. June 23 April 21 Workshop: Breakthrough November 30 Discussion Series: Business Models: Drug Discussion Series: A Conversation Science at FDA: Challenges Development for Rare with Tony Fauci and Opportunities and Neglected Diseases 2008 February 20–21 June 23–24 Discussion Series: Comparative Symposium: Diseases and Individualized Effectiveness (Forum Meeting #9)
|
From page 10... ...
response system is not well adapted to rapidly respond to a large number of diverse threats through adequate development and production of vaccines, therapeutics, diagnostic tools, and other nonpharmaceutical interventions. The Forum, in collaboration with the IOM's Forum on Medical and Public Health Preparedness for Catastrophic Events, will October 24 November 5 March 13 Workshop: Assessing and Workshop: Addressing the Threat Discussion Series: FDA Community Accelerating Development of of Drug-Resistant Tuberculosis: A Update on Personalized Medicine and Biomarkers for Drug Safety Realistic Assessment of the Challenge the Genetic Basis of Adverse Events 2009 February 23 November 3 Capitol Hill Briefing: Growing Forum Meeting #11 Threat of Drug-Resistant Tuberculosis
|
From page 11... ...
government. Further, the discussions at this meeting will be designed to identify and discuss what is needed to ensure that the private sector can respond in a rapid, nimble manner to ensure the availability of MCMs and explore advances made by the Public Health Emergency Medical Countermeasures Enterprise to improve MCM development and translation.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.